Stephens initiated coverage of Medifast with a rating of Equal-Weight and set a new price target of $82.00
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 11/5/2024 | $16.50 → $17.00 | Underperform → Neutral | DA Davidson |
| 6/5/2024 | $25.00 → $17.50 | Neutral → Underperform | DA Davidson |
| 10/13/2023 | $82.00 | Equal-Weight | Stephens |
| 11/4/2022 | $278.00 → $106.00 | Buy → Neutral | DA Davidson |
| 8/4/2022 | $345.00 → $150.00 | Buy → Hold | Jefferies |
| 2/24/2022 | $349.00 → $341.00 | Buy | DA Davidson |
| 11/8/2021 | $395.00 → $349.00 | Buy | DA Davidson |
Medifast (NYSE:MED), the health and wellness company known for its habit-based and coach-guided lifestyle solution, OPTAVIA®, today reported results for the third quarter ended September 30, 2024. Third Quarter 2024 Revenue of $140.2 million, with revenue per active earning coach of $4,672 Independent active earning OPTAVIA coaches of 30,000 Net income of $1.1 million (non-GAAP adjusted net income of $3.9 million) Income per diluted share of $0.10 (non-GAAP adjusted earnings per share ("EPS") of $0.35) Cash, Cash Equivalents, and Investment Securities of $170.0 million with no debt "Medical innovation has transformed the weight loss industry, so at Medifast we're creating a hea
Medifast (NYSE:MED), the health and wellness company known for its habit-based and coach-guided lifestyle solution, OPTAVIA®, will announce financial results for the third quarter ended September 30, 2024 on Monday, November 4, 2024, after market close. The Company will host a conference call to discuss the results with additional comments and details. Company participants will be Dan Chard, Chairman and Chief Executive Officer, and Jim Maloney, Chief Financial Officer. The conference call is scheduled to begin at 4:30 p.m. ET on November 4, 2024. The call will be broadcast live over the Internet, hosted on the Investor Relations section of Medifast's website at www.MedifastInc.com or dire
Medifast (NYSE:MED), the health and wellness company known for its habit-based and Coach-guided lifestyle solution, OPTAVIA®, today reported results for the second quarter ended June 30, 2024. Second Quarter 2024 Revenue of $168.6 million, with revenue per active earning Coach of $4,972 Independent active earning OPTAVIA Coaches of 33,900 Net loss of $8.2 million (non-GAAP adjusted net income of $10.1 million) Loss per diluted share of $0.75 (non-GAAP adjusted earnings per share ("EPS") of $0.92) Cash, Cash Equivalents, and Investment Securities of $163.5 million with zero debt "We are acting decisively to transform our business to position us for long-term growth, with
10-Q - MEDIFAST INC (0000910329) (Filer)
8-K - MEDIFAST INC (0000910329) (Filer)
S-8 - MEDIFAST INC (0000910329) (Filer)
4 - MEDIFAST INC (0000910329) (Issuer)
4 - MEDIFAST INC (0000910329) (Issuer)
4 - MEDIFAST INC (0000910329) (Issuer)
NEW YORK, June 7, 2024 /PRNewswire/ -- S&P Dow Jones Indices ("S&P DJI") will make the following changes to the S&P 500, S&P MidCap 400, and S&P SmallCap 600 indices effective prior to the open of trading on Monday, June 24, to coincide with the quarterly rebalance. The changes ensure each index is more representative of its market capitalization range. All companies being added to the S&P 500 are more representative of the large-cap market space, all companies being added to the S&P MidCap 400 are more representative of the mid-cap market space, and all companies being added to the S&P SmallCap 600 are more representative of the small-cap market space. The companies being removed from the S
BALTIMORE, March 2, 2023 /PRNewswire/ -- Medifast (NYSE:MED), the global company behind one of the fastest-growing health and wellness communities, OPTAVIA®, today announced it has named Steven Zenker as Vice President of Investor Relations. Mr. Zenker has over 30 years of investor relations, financial planning and analysis, communications, and investment management experience. He reports to Chief Financial Officer Jim Maloney and will lead the strategy and continued implementation of the company's investor relations program. "We are pleased to welcome Steven to the Medifast t
DA Davidson upgraded Medifast from Underperform to Neutral and set a new price target of $17.00 from $16.50 previously
DA Davidson downgraded Medifast from Neutral to Underperform and set a new price target of $17.50 from $25.00 previously
Stephens initiated coverage of Medifast with a rating of Equal-Weight and set a new price target of $82.00
DA Davidson analyst Linda Bolton Weiser maintains Medifast (NYSE:MED) with a Underperform and maintains $17.5 price target.
DA Davidson analyst Linda Bolton Weiser downgrades Medifast (NYSE:MED) from Neutral to Underperform and lowers the price target from $25 to $17.5.
Medifast (NYSE:MED), the health and wellness company known for its habit-based and coach-guided lifestyle solution, OPTAVIA®, today reported results for the third quarter ended September 30, 2024. Third Quarter 2024 Revenue of $140.2 million, with revenue per active earning coach of $4,672 Independent active earning OPTAVIA coaches of 30,000 Net income of $1.1 million (non-GAAP adjusted net income of $3.9 million) Income per diluted share of $0.10 (non-GAAP adjusted earnings per share ("EPS") of $0.35) Cash, Cash Equivalents, and Investment Securities of $170.0 million with no debt "Medical innovation has transformed the weight loss industry, so at Medifast we're creating a hea
Medifast (NYSE:MED), the health and wellness company known for its habit-based and coach-guided lifestyle solution, OPTAVIA®, will announce financial results for the third quarter ended September 30, 2024 on Monday, November 4, 2024, after market close. The Company will host a conference call to discuss the results with additional comments and details. Company participants will be Dan Chard, Chairman and Chief Executive Officer, and Jim Maloney, Chief Financial Officer. The conference call is scheduled to begin at 4:30 p.m. ET on November 4, 2024. The call will be broadcast live over the Internet, hosted on the Investor Relations section of Medifast's website at www.MedifastInc.com or dire
Medifast (NYSE:MED), the health and wellness company known for its habit-based and Coach-guided lifestyle solution, OPTAVIA®, today reported results for the second quarter ended June 30, 2024. Second Quarter 2024 Revenue of $168.6 million, with revenue per active earning Coach of $4,972 Independent active earning OPTAVIA Coaches of 33,900 Net loss of $8.2 million (non-GAAP adjusted net income of $10.1 million) Loss per diluted share of $0.75 (non-GAAP adjusted earnings per share ("EPS") of $0.92) Cash, Cash Equivalents, and Investment Securities of $163.5 million with zero debt "We are acting decisively to transform our business to position us for long-term growth, with
4 - MEDIFAST INC (0000910329) (Issuer)
4 - MEDIFAST INC (0000910329) (Issuer)
4 - MEDIFAST INC (0000910329) (Issuer)
SC 13G/A - MEDIFAST INC (0000910329) (Subject)
SC 13G - MEDIFAST INC (0000910329) (Subject)
SC 13G/A - MEDIFAST INC (0000910329) (Subject)